Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT

NCT03793517 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03793517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03793517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT
Lead sponsor
Peking University People's Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 1, 2018
Completion date
October 31, 2026
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia relapse, leukemia, myeloid, acute, stem cell transplant complications